(Press-News.org) A drug used to treat rheumatoid arthritis could also prevent the disease in individuals deemed to be at risk.
Results from a Phase 2b clinical trial, published today in The Lancet by researchers led by King’s College London, provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonising chronic inflammatory disease.
Rheumatoid arthritis affects half a million people in the UK and develops when the body’s immune system attacks itself, causing joint pain, swelling and significant disability. The disease most commonly begins in middle age, but much younger age groups can be afflicted, and until now there is no cure or prevention.
Abatacept is currently used as an effective second or third line treatment for people living with established rheumatoid arthritis and is given by weekly injections at home or in hospital via a drip.
Researchers from King’s College London recruited 213 patients at high risk of the disease to understand whether a year-long treatment of the biologic drug could be used to prevent progression to rheumatoid arthritis.
They recruited men and women over the age of 18 with early symptoms such as joint pain but no joint swelling, and treated half with the drug and half with a placebo every week for a year. The study drug was then stopped, and study participants monitored for a further 12 months.
After twelve months of treatment, 6% of patients treated with abatacept had developed arthritis compared to 29% in the placebo arm. By 24 months, the differences were still significant, with a total of 25% progressing to rheumatoid arthritis in the abatacept arm compared to 37% in the placebo arm.
Professor Andrew Cope, from King’s College London, said: “This is the largest rheumatoid arthritis prevention trial to date and the first to show that a therapy licensed for use in treating established rheumatoid arthritis is also effective in preventing the onset of disease in people at risk. These initial results could be good news for people at risk of arthritis as we show that the drug not only prevents disease onset during the treatment phase but can also ease symptoms such as pain and fatigue. This is also promising news for the NHS as the disease affects people as they age and will become more expensive to treat with a growing aging population.”
Secondary outcomes for the trial showed that abatacept was associated with improvements in pain scores, function and quality of life measurements, as well as lower scores of inflammation of the lining of joints detectable by ultrasound scan.
Philip Day, a 35-year-old software engineer and founder of FootballMatcher from Eltham, was at high-risk for rheumatoid arthritis. A keen football player, Philip’s joint pain deterred him from playing and affected his day-to-day life. He was enrolled in the trial in 2018, at the age of the 30, and was prescribed abatacept.
He said: “The pain got so terrible I stopped going to football, and I got lazier and felt progressively worse physically and mentally. The pain was unpredictable, it would show up in my knees one day, my elbows the next, and then my wrists or even my neck. At the time, my wife and I wanted to have children and I realised my future was pretty bleak if the disease progressed. I’d always wanted to be the kind of dad that played football with his son and I knew the pain would stop me from realising that dream.
“Enrolling in the trial was a no-brainer; it was a ray of hope at a dark time. Within a few months I had no more aches or pains and five years on I’d say I’ve been cured. Now, I can play football with my three-year-old son and have a normal life.”
One year’s treatment with abatacept costs the NHS about £10,000 per patient and is not without risk. Side effects include upper respiratory tract infections, dizziness, nausea and diarrhoea, but these are generally mild.
Professor Cope added: “There are currently no drugs available that prevent this potentially crippling disease. Our next steps are to understand people at risk in more detail so that we can be absolutely sure that those at highest risk of developing rheumatoid arthritis receive the drug.”
Rheumatologist Professor Sir Ravinder N Maini FRS FMedSci FRCP, who was not involved in the research, said: “Professor Cope and colleagues from King’s College, London, in collaboration with researchers in the UK and Netherlands, have published the results of an exciting clinical trial in The Lancet, which demonstrates that it is now possible to prevent the onset of RA, a disease that remains incurable despite great advances in its treatment in the recent past.
“The results clearly show that during the treatment period almost all individuals receiving the biologic drug showed no symptoms or signs of RA compared with the control population amongst many more developed RA. In the follow up period of 1 year off treatment, it is interesting to note that some appeared to go into remission.
“Prevention of disease is of course a highly desirable goal in preventing the ravages of disabling RA, which is associated with a significant social and financial burden. Many further questions arise from this important study. For example, will this preventive approach be safe and cost effective if continued long term or can the selection of suitable populations be refined so that only those likely to benefit most are treated with a short course of treatment?”
The APIPPRA trial is an Investigator-Sponsored Research (ISR) study, funded by Bristol Myers Squibb.
ENDS
END
Clinical trial shows rheumatoid arthritis drug could prevent disease
2024-02-14
ELSE PRESS RELEASES FROM THIS DATE:
Do apes have humor?
2024-02-14
Babies playfully tease others as young as eight months of age. Since language is not required for this behavior, similar kinds of playful teasing might be present in non-human animals. Now cognitive biologists and primatologists from the University of California Los Angeles (UCLA, US), the Max Planck Institute of Animal Behavior (MPI-AB, Germany), Indiana University (IU, US), and the University of California San Diego (UCSD, US) have documented playful teasing in four species of great apes. Like joking behavior in humans, ape teasing is provocative, persistent, and includes elements of surprise and play. Because all four great ape species used playful teasing, it is likely that the ...
New digital therapy reduces anxiety and depression in people living with long-term physical health conditions
2024-02-14
A therapist-guided digital cognitive behavioural therapy reduced distress in 89 per cent of participants living with long-term physical health conditions, a new King’s College London study finds.
Researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London found that people living with long-term conditions who received the therapist-guided digital programme called COMPASS showed a significant reduction in psychological distress (a combined score of anxiety and depression) 12-weeks after starting the study.
194 patients were recruited via long-term condition charities, including Crohn’s & ...
Researchers edge closer to delivering personalized medicine to cancer patients
2024-02-14
For the first time, Purdue researchers prove that measuring mechanical motions in living cancer tissues is a viable and promising approach for predicting chemoresistance
Chemotherapy can save lives, but often a cancer patient may be resistant to their prescribed chemotherapy, which costs the patient valuable time. Chemoresistance is a topic that researchers need to understand better so that they can match the right type of chemo to the right patient, which is called personalized medicine.
An unusual pairing of veterinary scientists and physicists believe ...
Trail cameras track ‘critically low’ New York bobcat population
2024-02-13
CORNELL UNIVERSITY MEDIA RELATIONS OFFICE
FOR RELEASE: Feb. 13, 2024
Kaitlyn Serrao
607-882-1140
kms465@cornell.edu
Trail cameras track ‘critically low’ New York bobcat population
ITHACA, N.Y. – With thousands of strategically placed cameras covering more than 27,000 square miles in central and western New York, biologists have evidence that bobcat populations remain critically low in central and western New York state.
Despite reports of recent recoveries elsewhere, bobcat populations in New York State displayed low occupancy, ...
Virginia Tech researchers discover that blocking an essential nutrient inhibits malaria parasite growth
2024-02-13
Living organisms often create what is needed for life from scratch.
For humans, this process means the creation of most essential compounds needed to survive. But not every living thing has this capability, such as the parasite that causes malaria, which affected an estimated 249 million people in 2022.
Virginia Tech researchers in the College of Agriculture and Life Sciences found that by preventing the malaria parasite from scavenging fatty acids, a type of required nutrient, it could no longer grow.
“The key to this breakthrough is that we were able to develop a screening method for the malaria ...
Children's Hospital Los Angeles researchers uncover social and economic factors that influence acute liver failure in children—and ways to overcome them
2024-02-13
Imagine your healthy child gets sick—so sick that you take them to the emergency department. You are shocked to find out that their liver is failing, and they will need a transplant to survive. Studies show that their chances of survival are higher the faster they can get to a hospital that performs liver transplants. But what factors affect how quickly that happens?
Pediatric acute liver failure, also called PALF, is a life-threatening condition that emerges with very little warning in previously healthy children. It is rare, affecting about 5,000 children in the United States a year, and can result from viral ...
Uncovering insights about prostate cancer risk and genetic ancestry
2024-02-13
This study included larger groups of people from African, Hispanic and Asian ancestries than many other previous studies.
A recent study involving scientists from the U.S. Department of Energy’s (DOE) Argonne National Laboratory has uncovered insights into the prostate cancer risks of people from a variety of genetic ancestries. The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs (VA) and DOE as ...
A century of reforestation helped keep the eastern US cool
2024-02-13
American Geophysical Union
13 February 2024
AGU Release No. 24-5
For Immediate Release
This press release and accompanying multimedia are available online at: https://news.agu.org/press-release/a-century-of-reforestation-helped-keep-the-eastern-us-cool/
A century of reforestation helped keep the eastern US cool
Much of the U.S. warmed during the 20th century, but the eastern part of the country remained mysteriously cool. The recovery of forests could explain why
AGU press contact:
Liza Lester, +1 (202) 777-7494, news@agu.org (UTC-5 hours)
Contact information for the researchers:
Kim ...
IL-17 promotes IL-18 production in osteoarthritis synovial fibroblasts via…
2024-02-13
“This study provides novel insights into the pathogenesis of OA and suggests a potential therapeutic target in OA treatment.”
BUFFALO, NY- February 13, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 2, entitled, “IL-17 promotes IL-18 production via the MEK/ERK/miR-4492 axis in osteoarthritis synovial fibroblasts.”
The concept of osteoarthritis (OA) as a low-grade inflammatory ...
New data speed record on optical fiber
2024-02-13
As data traffic continues to increase, there is a critical need for miniaturized optical transmitters and receivers that operate with high-order multi-level modulation formats and faster data transmission rates. In an important step toward fulfilling this requirement, researchers developed a new compact indium phosphide (InP)-based coherent driver modulator (CDM) and showed that it can achieve a record high baud rate and transmission capacity per wavelength compared to other CDMs. CDMs are optical transmitters used in optical communication systems that can put information on light by modulating the amplitude and phase before it is transmitted through optical fiber.
“Services that require ...